Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
CAMBRIDGE, Mass., April 06, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 4:20 p.m. ET in New York City.
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
